Condition: Coronary Artery Disease · Coronary Atherosclerotic Disease · Sponsor: Beijing Inno Medicine Co., Ltd.
This study is to evaluate the efficacy and safety of intravenously administered YN001 in patients with coronary atherosclerosis in Australia. This study will be conducted in eligible participants with a diagnosis of coronary atherosclerosis, and at least 1 coronary artery is blocked determined by coronary computed tomography angiography (CCTA)
This description comes directly from the study's public registry record.
Jean Zhang · 861082599080 · zhangjing@innovmedicine.com
Always discuss trial participation with your own doctor first.
| Canberra Hospital | Canberra, Australian Capital Territory, Australia | Recruiting |
| Albury Wodonga Private Hospital | Albury, New South Wales, Australia | Recruiting |
| Sunshine Coast University Private Hospital | Birtinya, Queensland, Australia | Recruiting |
| Core Research Group Pty Ltd | Milton, Queesland, Australia | Withdrawn |
| Altona Clinical Research | Melbourne, Victoria, Australia | Recruiting |
| Peninsula Heart Centre | Melbourne, Victoria, Australia | Recruiting |
| John Flynn Private Hospital | Tugun, Australia | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06700720